<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANP</journal-id>
<journal-id journal-id-type="hwp">spanp</journal-id>
<journal-title>Australian &amp; New Zealand Journal of Psychiatry</journal-title>
<issn pub-type="ppub">0004-8674</issn>
<issn pub-type="epub">1440-1614</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0004867412455702</article-id>
<article-id pub-id-type="publisher-id">10.1177_0004867412455702</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Correspondence</subject>
<subj-group subj-group-type="heading">
<subject>Letters</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>HLA-B*1502 screening in carbamazepine and lamotrigine candidates of Asian background</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hassan</surname><given-names>Islam</given-names></name>
</contrib>
<aff id="aff1-0004867412455702">Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville, Australia</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0004867412455702">Islam Hassan, Level 2, John Cade Building, Royal Melbourne Hospital Parkville, Victoria 3052, Australia. Email: <email>islam.hassan@mh.org.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>46</volume>
<issue>11</issue>
<fpage>1106</fpage>
<lpage>1107</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>To the Editor</p>
<p>The aromatic mood stabilisers carbamazepine and lamotrigine are routinely used in the management of bipolar affective disorder. One wonders to what extent pharmacogenetic findings over the past decade have influenced the prescription of these agents within the psychiatric community, specifically with regard to pre-prescription screening for the human leukocyte antigen (HLA) allele-B*1502 (HLA-B*1502) in patients of Asian background.</p>
<p>There is compelling evidence for the association of HLA-B*1502 with carbamazepine-induced Stevens– Johnson syndrome (SJS) to the extent that it was reported in <italic>Nature</italic> as the strongest ever association described between an HLA genotype and a disease (<xref ref-type="bibr" rid="bibr2-0004867412455702">Chung et al., 2004</xref>). In the studied Han Chinese population, 100% of 44 patients with carbamazepine-induced SJS tested positive for HLA-B*1502 while only 3% of 101 carbamazepine-tolerant patients were HLA-B*1502-positive. When the strength of this association is considered in conjunction with the high mortality rates associated with SJS and its more severe form, toxic epidermal necrolysis (TEN) – reported as about 10% and 50% respectively (<xref ref-type="bibr" rid="bibr5-0004867412455702">Mockenhaupt and Norgauer, 2002</xref>) – it is understandable that carbamazepine should be avoided in individuals of this genotype unless this risk is outweighed by expected benefit. The United States Food and Drug Administration issued an alert to this effect in 2007 (<xref ref-type="bibr" rid="bibr6-0004867412455702">U.S. Food and Drug Administration, 2007</xref>).</p>
<p>Notably, the HLA-B*1502 allele is present almost exclusively in individuals of East and Southeast Asian ethnicity including South Asian Indians (<xref ref-type="bibr" rid="bibr6-0004867412455702">U.S. Food and Drug Administration, 2007</xref>). Genetic testing for this allele is readily available for routine clinical practice and has been associated with a positive predictive value of up to 7.7% for carbamazepine-induced SJS/TEN in the Han Chinese population (<xref ref-type="bibr" rid="bibr3-0004867412455702">Hung et al., 2005</xref>). In the recent 3-year prospective study published in the <italic>New England Journal of Medicine</italic> (<xref ref-type="bibr" rid="bibr1-0004867412455702">Chen et al., 2011</xref>), out of 4120 patients of Han Chinese background who tested negative for HLA-B*1502 and subsequently received carbamazepine, none developed SJS/TEN. Based on historical control data, a Taiwanese population of similar size who had not been tested for the HLA-B*1502 allele would have been expected to develop 10 cases of carbamazepine-induced SJS/TEN. The authors concluded that genotyping for carbamazepine candidates in this population showed a strong association with reduced incidence of SJS/TEN.</p>
<p>With regard to patients considered for lamotrigine, there has not yet been a sufficiently large study to adequately characterize the possible association of this genotype with the risk of SJS/TEN. However, based on the similar aromatic structure to carbamazepine and evidence that the HLA-B*1502 is a common risk allele for both agents in inducing SJS/TEN (<xref ref-type="bibr" rid="bibr4-0004867412455702">Hung et al., 2010</xref>), caution is advisable at this stage in lamotrigine candidates of Asian background. In conclusion, given the evidence to date, it appears prudent to consider baseline testing for the HLA-B*1502 allele in carbamazepine and lamotrigine candidates of Asian background as part of routine practice.</p>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of interest</label>
<p>The author reports no conflicts of interest. The author alone is responsible for the content and writing of the paper.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0004867412455702">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>P</given-names></name>
<name><surname>Lin</surname><given-names>JJ</given-names></name>
<name><surname>Lu</surname><given-names>CS</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan</article-title>. <source>New England Journal of Medicine</source> <volume>364</volume>: <fpage>1126</fpage>–<lpage>1133</lpage>.</citation>
</ref>
<ref id="bibr2-0004867412455702">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chung</surname><given-names>WH</given-names></name>
<name><surname>Hung</surname><given-names>SI</given-names></name>
<name><surname>Hong</surname><given-names>HS</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Medical genetics: a marker for Stevens–Johnson syndrome</article-title>. <source>Nature</source> <volume>428</volume>: <fpage>486</fpage>.</citation>
</ref>
<ref id="bibr3-0004867412455702">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hung</surname><given-names>SI</given-names></name>
<name><surname>Chung</surname><given-names>WH</given-names></name>
<name><surname>Chen</surname><given-names>YT</given-names></name>
</person-group> (<year>2005</year>) <article-title>HLA-B genotyping to detect carbamazepine-induced Stevens–Johnson syndrome: implications for personalizing medicine</article-title>. <source>Personalized Medicine</source> <volume>2</volume>: <fpage>225</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr4-0004867412455702">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hung</surname><given-names>SI</given-names></name>
<name><surname>Chung</surname><given-names>WH</given-names></name>
<name><surname>Liu</surname><given-names>ZS</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese</article-title>. <source>Pharmacogenomics</source> <volume>11</volume>: <fpage>349</fpage>–<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr5-0004867412455702">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mockenhaupt</surname><given-names>M</given-names></name>
<name><surname>Norgauer</surname><given-names>J</given-names></name>
</person-group> (<year>2002</year>) <article-title>Cutaneous adverse drug reactions: Stevens–Johnson syndrome and toxic epidermal necrolysis</article-title>. <source>Allergy &amp; Clinical Immunology International</source> <volume>14</volume>: <fpage>143</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr6-0004867412455702">
<citation citation-type="gov">
<collab>U.S. Food and Drug Administration</collab> (<year>2007</year>) <article-title>Information for Healthcare Professionals: Dangerous or even fatal skin reactions – Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics</article-title>. FDA Alert 12/12/2007. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.html">www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.html</ext-link> (<access-date>accessed 7 July 2012</access-date>).</citation>
</ref>
</ref-list>
</back>
</article>